Patient savings card(s)

For eligible commercial patients pay as little as $30 for Glucagon.*

Each card has a unique ID number. Please do not make copies.

Thank you for downloading your Glucagon Savings Card! Your download has begun. If there is a problem, try downloading again.

Sorry, there was a problem downloading your card(s)

*Qualifying patients with commercial insurance coverage may be eligible to pay as little as $30 for a maximum of 3 Lilly Glucagon emergency kits per prescription fill. Offer is subject to a monthly cap of $100 and a separate annual maximum cap of $1200. Offer is good for up to 12 months from card activation/patient qualification. Patients may be able to re-enroll if they continue to qualify. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by Medicare Part D, Medicaid, TRICARE or any other state or federal program.

Indication and Important Safety Information
IMPORTANT SAFETY INFORMATION FOR GLUCAGON
  • Contraindications Glucagon is contraindicated in patients with known hypersensitivity to it or in patients with known pheochromocytoma.
  • Warnings and Precautions
    • Glucagon should be administered cautiously to patients with a history suggestive of insulinoma, pheochromocytoma, or both. In patients with insulinoma, intravenous administration of Glucagon may produce an initial increase in blood glucose; however, because of Glucagon’s hyperglycemic effect the insulinoma may release insulin and cause subsequent hypoglycemia. A patient developing symptoms of hypoglycemia after a dose of Glucagon should be given glucose orally, intravenously, or by gavage, whichever is most appropriate.
    • Exogenous Glucagon also stimulates the release of catecholamines. In the presence of pheochromocytoma, glucagon can cause the tumor to release catecholamines, which may result in a sudden and marked increase in blood pressure.
    • Generalized allergic reactions, including urticaria, respiratory distress, and hypotension, have been reported in patients who received Glucagon by injection.
    • Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported post marketing following continuous glucagon infusion. Lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases, NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.
    • Glucagon is effective in treating hypoglycemia only if sufficient liver glycogen is present. Therefore, hypoglycemia associated with states of starvation, adrenal insufficiency, or chronic hypoglycemia should be treated with glucose.
    • Patients and family members should become familiar with the technique of preparing Glucagon before a severe hypoglycemic emergency arises.
    • To reduce the likelihood of severe hypoglycemia, patients and family members should be informed of the symptoms of mild hypoglycemia and how to treat it appropriately. Blood glucose determinations should be obtained to monitor the patient with hypoglycemia until the patient is asymptomatic, and patients should be advised to inform their physician when hypoglycemic reactions occur.
    • One-half the adult dose should be used in pediatric patients weighing less than 44 lbs (20 kg). Any unused portion should be discarded.
    • There are no adequate and well-controlled clinical studies of the use of Glucagon in pregnant or nursing women.
  • Adverse Reactions
    • Side effects may include nausea and vomiting.
GL HCP ISI 12Jul2018